COMMUNIQUÉS West-GlobeNewswire

Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified

29/08/2017 - 07:00

Unique binding mode of PBD-C06 to pGlu-Abeta peptides identified Probiodrug publishes mechanism of target binding for its lead anti-pGlu-Abeta monoclonal antibody PBD-C06 HALLE (SAALE), Germany, 29 August 2017 - [...]

Solon Eiendom ASA : Q2 2017 All-time high sales value

29/08/2017 - 06:30

(Oslo, Norway, 29 August 2017) Solon Eiendom ASA (OSE:SOLON) is presenting the Q2 2017 report at 08.30 am CET at Sparebank 1 Markets, Olav Vs gate 5 in Oslo. The quarterly presentation materials is enclosed and will be [...]

Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant

28/08/2017 - 22:04

DANVERS, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its [...]

ProMIS Neurosciences Completes Second Closing of Private Placement

28/08/2017 - 21:00

TORONTO, Aug. 28, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN) (OTCPK:ARFX.F) (DB:23J) is pleased to announce that, further to its news releases dated July 20, 2017, August 2 [...]

Ossur Hf : Transactions in relation to share buyback program

28/08/2017 - 18:00

Announcement from Össur hf. No. 64/2017 Reykjavík, 28 August 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Sanofi : Disclosure of trading in own shares

28/08/2017 - 18:00

Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]

Sanofi : Déclaration des transactions sur actions propres

28/08/2017 - 18:00

Reporting FR This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, [...]

Novo Nordisk A/S - Share repurchase programme

28/08/2017 - 14:00

Bagsværd, Denmark, 28 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Interim Data on MobiusHD Presented at the European Society of Cardiology Shows Promise in the Treatment of Resistant Hypertension

28/08/2017 - 14:00

MOUNTAIN VIEW, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announced interim [...]

Shire plc : MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S.

28/08/2017 - 13:00

For U.S. Audiences Only MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S. Mydayis, which is now available in the U.S., demonstrated [...]

Medtronic Plans for Renal Denervation Pivotal Trial After New Study Shows Significant Blood Pressure Reductions

28/08/2017 - 11:14

Published Simultaneously in The Lancet , the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure DUBLIN and BARCELONA [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

28/08/2017 - 09:00

FIT Biotech Oy Company release August 28, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - June 30, 2017

28/08/2017 - 08:00

Message from the CEO IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations for a subsequent phase III clinical trial. The phase II clinical [...]

Sanofi completes the acquisition of Protein Sciences

28/08/2017 - 07:00

Sanofi completes the acquisition of Protein Sciences - An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio - Paris, France - August 28, 2017 - Sanofi announced today that it has [...]

Sanofi finalise l'acquisition de Protein Sciences

28/08/2017 - 07:00

Sanofi finalise l'acquisition de Protein Sciences - Un vaccin antigrippal quadrivalent innovant viendra compléter la gamme de vaccins de Sanofi Pasteur - Paris, France - Le 28 août 2017 - Sanofi annonce aujourd'hui [...]

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs

28/08/2017 - 07:00

1. Settlement of vested restricted stock units ("RSUs") Robert Burns, member of the board of directors of Targovax ASA (the "Primary Insider"), has on 25 August 2017 subscribed for 40,984 shares in Targovax ASA at a [...]

Santhera to Publish First Half-Year Report and Corporate Update on September 5, 2017

28/08/2017 - 07:00

Liestal, Switzerland, August 28, 2017 - Santhera Pharmaceuticals (SIX: SANN) will publish its 2017 first half-year report and corporate update on Tuesday, September 5, 2017 at 07:00 CET. An investor conference call with [...]

Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

27/08/2017 - 11:00

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard [...]

Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned

27/08/2017 - 11:00

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III [...]